

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>	Docket No. <b>ORT-1541</b>	Serial No. <b>09/994,153</b>
	Applicant <b>Hutchings et al.</b>	
	Filing Date	Group Art Unit <b>162-1</b>

1002 U.S. PTO  
09/994153  
11/26/01

## U.S. PATENT DOCUMENTS

Exam'r Init.	Document No.	Date	Name	Class	Sub Class	File Date
RR	5,332,732	7/26/94	Scott et al.	514	212	9/11/92
RR	5,605,896	2/25/97	Leonardi et al.	514	218	8/31/94

## FOREIGN PATENT DOCUMENTS

Exam'r Init.	Document No.	Date	Country	Class	Sub Class	Translate (select one) Yes No	
RR	0 416 841 A2	3/13/91	EPO	<del>A61K</del>	<del>31/505</del>	<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER REFERENCES (include author, title, date, pertinent pages, etc.)

RR	Scott M.K. et al. (1995) Piperazinylalkyl Heterocycles as Potential Antipsychotic Agents. Journal of Medicinal Chemistry. Vol. 38, No. 21: 4198-4210.
RR	Reitz A. B. et al. (1995) N-Aryl-N-Benzylpiperazines as Potential Antipsychotic Agents. Journal of Medicinal Chemistry. Vol. 38, No. 21: 4211-4222.
RR	Reitz A. B. et al. (1994) A New Arylpiperazine Antipsychotic with High D2/D3/5-HT1A/ $\alpha$ 1A-Adrenergic Affinity and A Low Potential for Extrapyrimal Effects. Vol. 37, No. 8: 1060-1062.
RR	PCT International Search Report of PCT/US 98/21470, 1998

Examiner: <b>R Raymon</b>	Date Considered <b>2-21-03</b>
Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

Form PTO-1449

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

Docket No.

ORT-1541

Serial No.

09/994,153

Applicant

Hutchings et al.

Filing Date

Group Art Unit

1624

## U.S. PATENT DOCUMENTS

Exam'r Init.	Document No.	Date	Name	Class	Sub Class	File Date
RR	5,403,847	4/4/95	Gluchowski et al.	514	318	11/13/92

## FOREIGN PATENT DOCUMENTS

Exam'r Init.	Document No.	Date	Country	Class	Sub Class	Translate (select one)	
						Yes	No
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER REFERENCES (include author, title, date, pertinent pages, etc.)

		Please see attached sheet for list of other references

Examiner:

R Raymond

Date Considered

2-21-03

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

39994153

RR		Breslin D, Fields DW, Chou T-C, Marion DN, Kané M, Vaughan ED, and Felsen D (1993) Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. J. Urol. 149: 395-399.
RR		Bruno JF, Whittaker J, Song J, and Berelowitz M. (1991) Molecular cloning and sequencing of a cDNA encoding a human $\alpha$ 1A adrenergic receptor. Biochem. Biophys. Res. Commun. 179: 1485-1490.
RR		Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR, and Trendelenburg U (1994) IV. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46: 121-136.
RR		Carruthers SG (1994) Adverse effects of $\alpha$ 1-adrenergic blocking drugs. Drug Safety 11: 12-20.
RR		Faure C, Gouhier C, Langer SZ, and Graham D (1995) Quantification of $\alpha$ 1-adrenoceptor subtypes in human tissues by competitive RT-PCR analysis. Biochem. Biophys. Res. Commun. 213: 935-943.
RR		Flavahan NA and VanHoutte PM (1986) $\alpha$ 1-Adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol. Sci. 7: 347-349.
RR		Ford APDW, Arredondo NF, Blue DR, Bonhaus DW, Jasper J Kava MS, Lesnick J, Pfister JR, Shieh IA, Vimont RL, Williams TJ, McNeal JE, Stamey TA, and Clarke DE (1996) RS-17053 (N-[2-(2-Cyclopropylmethoxyphenoxy)ethyl]-5-chloro-a, a-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective $\alpha$ 1A-adrenoceptor antagonist, displays low affinity for functional $\alpha$ 1-adrenoceptors in human prostate: Implications for adrenoceptor classification. Mol. Pharmacol. 49: 209-215.
RR		Forray C, Bard JA, Wegzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, and Gluchowski C (1994) The $\alpha$ 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human $\alpha$ 1c subtype. Mol. Pharmacol. 45: 703-708.
RR		Gormley G, Stoner E, Bruskewitz RC et al. (1992) The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 327: 1185-1191.
RR		Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, and Takeda M (1994) Pharmacological evidence of distinct $\alpha$ 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br. J. Pharmacol. 113: 723-728.

R Raymond 2-21-03

09/04/53

RR	Harrison JK, Pearson WR, and Lynch KR (1991) Molecular characterization of $\alpha$ 1- and $\alpha$ 2-adrenoceptors. Trends Pharmacol. Sci. 12: 62-67.
RR	Hieble JP and Caine M (1986) Etiology of benign prostatic hyperplasia and approaches to pharmacological management. Fed. Proc. 45: 2601 - 2603.
RR	Hirasawa A, Horie K, Tanaka T, Takagaki K, Murai M, Yano J, and Tsujimoto G (1993) Cloning, functional expression and tissue distribution of human cDNA for the $\alpha$ 1c-adrenergic receptor. Biochem. Biophys. Res. Commun. 195: 902-909.
RR	Holck MI, Jones CHM, and Haeusler G (1983) Differential interactions of clonidine and methoxamine with postsynaptic $\alpha$ -adrenoceptors of rabbit main pulmonary artery. J. Cardiovasc. Pharm. 5: 240-248.
RR	Lepor H and Rigaud G (1990) The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J. Urol. 143: 533-537.
RR	Lepor H, Auerbach S, Puras-Baez A et al. (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol. 148: 1467-1474.
RR	Lepor H (1995) $\alpha$ -Blockade for benign prostatic hyperplasia (BPH) J. Clin. Endocrinol. Metab. 80: 750-753.
RR	Marshall I, Burt RP, Andersson PO, Chapple CR, Greengrass PM, Johnson GI, and Wyllie MG (1992) Human $\alpha$ 1c-adrenoceptor: functional characterisation in prostate. Br. J. Pharmacol. 107(Proc. Suppl. Dec.):327P.
RR	Marshall I, Burt RP, and Chapple CR (1995) Noradrenaline contractions of human prostate mediated by $\alpha$ 1A- ( $\alpha$ 1c-) adrenoceptor subtype. Br. J. Pharmacol. 115: 781-786.
RR	Mebust WK, Holtgrewe HL, Cockett ATK, and Peters PC (1989) Transurethral prostatectomy: immediate and postoperative complication: a cooperative study of 13 participating institutions evaluating 3,885 patients. J. Urol. 141: 243-247.
RR	Minneman KP, Han C and Abel PW (1988) Comparison of $\alpha$ 1-adrenergic receptor subtypes distinguished by chloroethylclonidine and WB4101. Mol. Pharmacol. 33: 509-514.
RR	Minneman KP and Esbenshade TA (1994) $\alpha$ 1-Adrenergic receptor subtypes. Annu. Rev. Pharmacol. Toxicol. 34: 117-133.
RR	Morrow AL and Creese I (1986) Characterization of $\alpha$ 1-adrenergic receptor subtypes in rat brain: A reevaluation of [3H]WB4104 and [3H]prazosin binding. Mol. Pharmacol. 29: 321-330.

RR Raymond

2-21-03

09/994153

IR	Muramatsu I (1992) A pharmacological perspective of $\alpha$ 1-adrenoceptors: subclassification and functional aspects, in $\alpha$ -Adrenoceptors (Fujiwara M, Sugimoto T, and Kogure K, eds.). Excerpta Medica Ltd., Tokyo, 193-202.
IR	Muramatsu I, Oshita M, Ohmura T, Kigoshi S, Akino H, Gobara M, and Okada K (1994) Pharmacological characterization of $\alpha$ 1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br. J. Urol. 74: 572-577.
IR	Oesterling JE (1995) Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N. Engl. J. Med. 332: 99-109.
IR	Price DT, Lefkowitz RJ, Caron MG, Berkowitz D, and Schwinn DA (1994) Localization of mRNA for three distinct $\alpha$ 1-adrenergic receptor subtypes in human tissues: implications for human $\alpha$ -adrenergic physiology. Mol. Pharmacol. 45: 171-175.
IR	Ramarao CS, Kincade Denker JM, Perez DM, Gaivin RJ, Riek RP, and Graham RM (1992) Genomic organization and expression of the human $\alpha$ 1B-adrenergic receptor. J. Biol. Chem. 267: 21936-21945.
IR	Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, Peter B, and Bailey DS (1995) Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. JPET 272: 134-142.
IR	Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, and Bayne M (1994) Cloning, expression and characterization of human $\alpha$ adrenergic receptors $\alpha$ 1A, $\alpha$ 1B, and $\alpha$ 1C. Biochem. Biophys. Res. Commun. 201: 1296-1304.
RP	Weis KA, Epstein RS, Huse DM, Deverka PA and Oster G (1993) The costs of prostatectomy for benign prostatic hyperplasia. Prostate 22: 325-334.
IR	Wennberg JE, Roos N, Sola L, Schori A, and Jaffe R (1987) Use of claims data systems to evaluate health care outcomes: mortality and reoperation following prostatectomy. JAMA 257: 933-936.
RP	Yamada S, Tanaka C, Kimura R, and Kawabe K (1994) Alpha 1-adrenoceptors in human prostate: characterization and binding characteristics of alpha 1-antagonists. Life Sci. 54: 1845-1854.

R. Rayner

2-21-03